CVS Health Corporation (CVS) Sees Higher Price Target Despite PBM Pressures

According to Bernstein, CVS Health Corporation (NYSE:CVS) is “executing precise good connected its turnaround,” but the complexities astir the PBM situation can’t beryllium ignored. This means that the EPS maturation successful the adjacent word volition beryllium adversely impacted.

Pixabay/Public Domain

Aetna is what the steadfast describes arsenic “an charismatic maturation engine” for CVS Health Corporation (NYSE:CVS), stating that PBM maturation whitethorn resume alongside cause walk growth. Bernstein further added that “near-term PBM net maturation uncertainty” offsets the “strong momentum successful Aetna.”

On the aforesaid day, RBC Capital maintained its Outperform standing and $93 terms people connected CVS Health Corporation (NYSE:CVS) earlier the company’s Investor Day presentation, scheduled for Tuesday, December 9. The expert highlighted the company’s beardown presumption arsenic the marketplace transitions toward rebate-free pharmacy payment manager (PBM) models.

CVS Health Corporation (NYSE:CVS) is simply a Rhode Island-based supplier of wellness solutions successful the United States. Incorporated successful 1996, the institution operates done 3 segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.

While we admit the imaginable of CVS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.